Breaking new ground in treating hypertrophic cardiomyopathy
The biopharmaceutical company Bristol Myers Squibb (BMS) placed hypertrophic cardiomyopathy at the core of a recent Nicosia press conference, held under the auspices of the Cyprus Society of Cardiology.
Cypriot ...